{"log_id": 1215885844367108166, "direction": 0, "words_result_num": 32, "words_result": [{"probability": {"variance": 0, "average": 0.998822, "min": 0.998822}, "location": {"width": 34, "top": 84, "height": 31, "left": 1155}, "words": "局"}, {"probability": {"variance": 0.004932, "average": 0.979051, "min": 0.511037}, "location": {"width": 822, "top": 173, "height": 40, "left": 210}, "words": "贫血的发生率为58.7%(其中8%Hb小于8g/d1,0.9%Hb小于6.5g/dl)。7.4%的患者(1.8"}, {"probability": {"variance": 0.001305, "average": 0.986532, "min": 0.771184}, "location": {"width": 817, "top": 221, "height": 38, "left": 209}, "words": "%的治疗周期)出现血小板减少症(小于100,000/m3),其中0.9%(0.2%的治疗周期)"}, {"probability": {"variance": 0, "average": 0.99698, "min": 0.99698}, "location": {"width": 44, "top": 231, "height": 27, "left": 1147}, "words": "国"}, {"probability": {"variance": 0.00025, "average": 0.994026, "min": 0.920079}, "location": {"width": 583, "top": 273, "height": 28, "left": 209}, "words": "的患者血小板计数≤50,000/m3,几乎所有患者均在第22天恢复"}, {"probability": {"variance": 0.000254, "average": 0.995576, "min": 0.899453}, "location": {"width": 793, "top": 317, "height": 44, "left": 208}, "words": "在联合治疗A82.5%的患者出现中性粒细胞减少症,严重者(中性粒细胞计数小于"}, {"probability": {"variance": 0.031281, "average": 0.879413, "min": 0.380094}, "location": {"width": 815, "top": 366, "height": 38, "left": 213}, "words": "00m点8%在可评价的治疗周期内,67.3%出现中性料胞计011,000/m,其"}, {"probability": {"variance": 0.007868, "average": 0.966172, "min": 0.546325}, "location": {"width": 580, "top": 415, "height": 34, "left": 211}, "words": "中2.7%中性粒细胞计数<500/mm。通常在7-8天内完全恢复正常"}, {"probability": {"variance": 0.002115, "average": 0.986963, "min": 0.742895}, "location": {"width": 811, "top": 463, "height": 37, "left": 205}, "words": "34%的患者(0.92的治疗周期)出现严重中性粒细胞减少症合并发热。2%的患者(0.5"}, {"probability": {"variance": 0.000706, "average": 0.992409, "min": 0.826475}, "location": {"width": 819, "top": 510, "height": 39, "left": 207}, "words": "%的治疗周期)出现感染;2.1%的患者(0.5%的治疗周期)出现严重中性粒细胞减少症合"}, {"probability": {"variance": 0.000348, "average": 0.993235, "min": 0.93726}, "location": {"width": 199, "top": 560, "height": 27, "left": 204}, "words": "并感染,1例导致死亡"}, {"probability": {"variance": 0.003527, "average": 0.984716, "min": 0.572917}, "location": {"width": 821, "top": 607, "height": 36, "left": 203}, "words": "贫血的发生率为97.2%(2.1%Hb小于8g/dl)。32.6%的患者(21.8%的治疗周期)出现血"}, {"probability": {"variance": 0.00555, "average": 0.977899, "min": 0.58725}, "location": {"width": 825, "top": 653, "height": 42, "left": 202}, "words": "小板减少症(小于100,000/m3),未观察到严重血小板减少症出现(小于50,000/m3)。"}, {"probability": {"variance": 2.5e-05, "average": 0.997742, "min": 0.975092}, "location": {"width": 601, "top": 702, "height": 34, "left": 203}, "words": "在败血症患者中,肾功能不全、低血压或心脏及循环系统衰竭罕见"}, {"probability": {"variance": 2e-06, "average": 0.999007, "min": 0.993174}, "location": {"width": 683, "top": 749, "height": 36, "left": 201}, "words": "在上市后使用中,曾报导一例因抗血小板抗体导致外周血小板减少症的病例"}, {"probability": {"variance": 1e-06, "average": 0.99928, "min": 0.996834}, "location": {"width": 234, "top": 797, "height": 32, "left": 199}, "words": "常见不适及注射部位反应"}, {"probability": {"variance": 0.002451, "average": 0.989104, "min": 0.686086}, "location": {"width": 821, "top": 844, "height": 40, "left": 199}, "words": "急性胆碱能综合征:在单药治疗中9%的患者出现短暂严重的急性胆碱能综合征,而在联合治"}, {"probability": {"variance": 0.00731, "average": 0.974921, "min": 0.526642}, "location": {"width": 798, "top": 892, "height": 38, "left": 198}, "words": "疗中仅为1.4%。主要症状为:早发性腹泻及其他症状,例如:用药后第一个24小时内发生"}, {"probability": {"variance": 6.2e-05, "average": 0.997957, "min": 0.950097}, "location": {"width": 818, "top": 939, "height": 39, "left": 197}, "words": "腹痛、结膜炎、鼻炎、低血压、血管舒张、出汗、寒战、全身不适、头晕、视力障碍、瞳孔"}, {"probability": {"variance": 0.000601, "average": 0.991148, "min": 0.887239}, "location": {"width": 504, "top": 987, "height": 34, "left": 196}, "words": "缩小、流泪及流涎增多。以上症状于阿托品治疗后消失"}, {"probability": {"variance": 0.000285, "average": 0.993505, "min": 0.895118}, "location": {"width": 818, "top": 1035, "height": 41, "left": 197}, "words": "在单药治疗中少于10%的患者出现严重乏力,而在联合治疗中为6.2%。其与使用本品的确"}, {"probability": {"variance": 7e-06, "average": 0.998242, "min": 0.991723}, "location": {"width": 146, "top": 1086, "height": 26, "left": 199}, "words": "切关系尚未阐明"}, {"probability": {"variance": 7e-06, "average": 0.998355, "min": 0.988155}, "location": {"width": 821, "top": 1131, "height": 42, "left": 194}, "words": "在单药治疗中12%的患者在无感染及严重中性粒细胞减少症的情况下出现发热,而在联合治"}, {"probability": {"variance": 8e-06, "average": 0.998423, "min": 0.991662}, "location": {"width": 117, "top": 1182, "height": 25, "left": 194}, "words": "疗中为6.2%"}, {"probability": {"variance": 4e-06, "average": 0.998685, "min": 0.993672}, "location": {"width": 420, "top": 1228, "height": 35, "left": 193}, "words": "轻度注射部位反应,尽管不常见,但也有报导"}, {"probability": {"variance": 0.003818, "average": 0.987261, "min": 0.60498}, "location": {"width": 820, "top": 1276, "height": 42, "left": 192}, "words": "呼吸系统病症:罕见间质性肺炎及局限性肺炎引起的肺部侵润。早期的反应如呼吸困难也有"}, {"probability": {"variance": 0, "average": 0.999668, "min": 0.999646}, "location": {"width": 47, "top": 1326, "height": 25, "left": 190}, "words": "报导"}, {"probability": {"variance": 1.4e-05, "average": 0.998228, "min": 0.978115}, "location": {"width": 778, "top": 1374, "height": 41, "left": 191}, "words": "皮肤及皮下组织病症:常见脱发,为可逆转的。轻度皮肤反应尽管不常见,但也有报导"}, {"probability": {"variance": 0.002643, "average": 0.988385, "min": 0.712914}, "location": {"width": 613, "top": 1423, "height": 36, "left": 190}, "words": "免疫系统病症:轻度不常见的变态反应以及罕见的过敏反应也有报导"}, {"probability": {"variance": 0.002435, "average": 0.98665, "min": 0.733148}, "location": {"width": 615, "top": 1470, "height": 39, "left": 189}, "words": "肌肉骨骼病症:早期的反应如肌肉收缩、痉挛及感觉异常等均有报导"}, {"probability": {"variance": 1e-06, "average": 0.999217, "min": 0.996866}, "location": {"width": 105, "top": 1520, "height": 26, "left": 190}, "words": "实验室检查"}, {"probability": {"variance": 0.000139, "average": 0.995628, "min": 0.934903}, "location": {"width": 819, "top": 1567, "height": 41, "left": 188}, "words": "单药治疗一一在无进展性肝转移的患者中,血清中短暂、轻至中度转氨酶、碱性磷酸酶、胆"}], "language": 3}